Study ID: TV48574-AS-20031 | 2020-001927-15
Study Title
- A Study to Test if TEV-48574 is Effective in Relieving Asthma
Teva Identifier
- TV48574-AS-20031 | 2020-001927-15
ClinicalTrials.gov Identifier
- NCT04545385
Study Status
- Terminated
Trial Condition(s)
- Asthma
Interventions
- Drug: TEV-48574 | Drug: Placebo
EudractCT Number
- 2020-001927-15
Study Description
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult patients with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).
The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.
The duration of patient participation in the study is planned to be up to approximately 30 weeks.
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years and older
Trial Duration
- August 25, 2020 - January 17, 2022
Phase
- Phase 2
Study Type
Interventional
